High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.
about
Adenoviral vector immunity: its implications and circumvention strategies.The influence of innate and pre-existing immunity on adenovirus therapyNerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS.Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsGene transfer into rat brain using adenoviral vectors.Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells.Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms.Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialSafety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaPreclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma ModelViruses, gene therapy and stem cells for the treatment of human glioma.Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for gliomaAdenovirus-mediated expression of BmK CT suppresses growth and invasion of rat C6 glioma cells.Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy.Gene therapy and targeted toxins for glioma
P2860
Q33565630-AA8E6DBB-DA02-4087-81EB-8C910EC8D859Q33655401-891A34A0-D61A-455B-8659-14B0ADB2F580Q33742711-242D8CA1-7B31-4C34-906C-69698A2DD09DQ33828114-F4575141-A6EA-48C7-BA1A-329E4C8E0F41Q33877450-5FD22BC7-9D8E-4AB5-B2CA-671EBF67F24CQ33904294-51146305-39D6-4461-9F92-D746D7A2F3C3Q34012284-D2E91578-D7CD-410F-A660-5B69D6AB6276Q34976249-47C2A1B4-3968-40FB-8725-807989CCCC1AQ36367568-BF843FF6-2CFB-4EB5-999F-A19A58911FF4Q36534329-CCA92EA7-685E-4625-ABF3-903B5F21EB89Q36811505-A9F1A494-1339-4C34-96E4-F98188FB9770Q37050094-003F3407-2299-4A00-B54F-94BBDB46375CQ37567452-20CEAE17-17ED-411C-B899-F2EFD5D4159FQ37730116-C60DEB0C-1546-4634-8797-48BBF3EE28FEQ39188207-F64CC007-8CB3-41C0-B481-010DBD26D1C9Q51847569-EE84184B-3175-45EF-A82D-4D3E76DD38C7Q57006162-8BA03DB5-0914-48B5-9A94-AF3406DBB537
P2860
High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
High-capacity adenovirus vecto ...... temic antiadenovirus immunity.
@ast
High-capacity adenovirus vecto ...... temic antiadenovirus immunity.
@en
type
label
High-capacity adenovirus vecto ...... temic antiadenovirus immunity.
@ast
High-capacity adenovirus vecto ...... temic antiadenovirus immunity.
@en
prefLabel
High-capacity adenovirus vecto ...... temic antiadenovirus immunity.
@ast
High-capacity adenovirus vecto ...... temic antiadenovirus immunity.
@en
P2093
P2860
P356
P1433
P1476
High-capacity adenovirus vecto ...... stemic antiadenovirus immunity
@en
P2093
A K M Ghulam Muhammad
Daniel Larocque
Donna Palmer
Gwendalyn D King
Kurt M Kroeger
Mariana Puntel
Pedro R Lowenstein
Weidong Xiong
P2860
P304
P356
10.1128/JVI.00232-08
P407
P577
2008-02-20T00:00:00Z